APS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 20.20%

Insider Buying (Last 12 Months): C$0.00

Insider Selling (Last 12 Months): C$0.00

Aptose Biosciences Insider Trading History Chart

Aptose Biosciences Share Price & Price History

C^$1.69

▼ -0.06 (-3.43%)

As of 04/19/2024 01:00 AM ET

Days: 30 | 90 | 365

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Aptose Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/19/2022	William Glenn Rice	Director	Buy	5,700	C$0.88	C$5,025.04	358,952
6/6/2022	William Glenn Rice	Director	Buy	2,776	C$1.22	C$3,375.69	346,028
12/20/2021	Denis Burger	Director	Buy	10,000	C$1.87	C$18,692.10	31,671
12/16/2021	William Glenn Rice	Director	Buy	3,183	C$1.92	C$6,111.36	333,252
11/26/2021	William Glenn Rice	Director	Buy	1,000	C$3.07	C$3,069.00	304,604
11/19/2021	Rafael Bejar	Senior Officer	Buy	10,000	C$3.38	C$33,792.00	10,000
6/21/2021	Warren Whitehead	Director	Sell	15,400	C$4.15	C$63,848.40	24,600

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

Claim your free seat by clicking here now.

SEC Filings (Institutional Ownership Changes) for Aptose Biosciences (TSE:APS)

9.80% of Aptose Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Today's Range

Now: C$1.69

C$1.69

C$1.73

50 Day Range

MA: C$2.18

C$1.69

C$2.78

52 Week Range

Now: C$1.69

C$1.69

C$11.40

Volume

20,800 shs

Average Volume

9,029 shs

Market Capitalization

C$26.55 million

P/E Ratio

N/A

Dividend Yield

0.39%

Beta

1.44

Who are the company insiders with the largest holdings of Aptose Biosciences?: Aptose Biosciences' top insider investors include:
William Glenn Rice (Director)
Learn More about top insider investors at Aptose Biosciences.